TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study

(2021) Kimberly K. Leslie et al.   GYNECOLOGIC ONCOLOGY

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

(2020) Alicia León-Castillo et al.   JOURNAL OF CLINICAL ONCOLOGY

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

(2020) Eun Young Kang et al.   MODERN PATHOLOGY

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

(2020) Anne Sophie V M van den Heerik et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

(2020) David S. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens

(2019) Anna Plotkin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies

(2019) Naveena Singh et al.   JOURNAL OF PATHOLOGY

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer

(2018) Carol Aghajanian et al.   GYNECOLOGIC ONCOLOGY

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial

(2018) B.G. Wortman et al.   GYNECOLOGIC ONCOLOGY

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

(2016) Ellen Stelloo et al.   CLINICAL CANCER RESEARCH

A clinically applicable molecular-based classification for endometrial cancers

(2015) A Talhouk et al.   BRITISH JOURNAL OF CANCER

USA Endometrial Cancer Projections to 2030: should we be concerned?

(2014) M Aamir Sheikh et al.   Future Oncology

TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma

(2014) PAVLA BRACHOVA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer

(2013) Pavla Brachova et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

(2011) Anna Yemelyanova et al.   MODERN PATHOLOGY

p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes

(2009) Karuna Garg et al.   MODERN PATHOLOGY